Thursday, June 13, 2019 11:59:52 AM
Koffler said she attributes a 40% share selloff of the company's stock since April to financing uncertainty and the "lackluster" performance of the prescription anticholinergi Qbrexza.
"We believe Dermira could be strategically attractive to dermatology-focused companies," Koffler wrote. "We believe there could be significant cost synergies associated with cutting Qbrexza SG&A (Selling, General and Administrative Expenses)."
Koffler said that "the chief risk to our thesis is that Almirall walks away from EU rights."
"If Almirall abandons the deal, it may discourage other strategic interest in lebrikizumab as well," she wrote. "In this case, it's possible that Dermira would need to develop lebrikizumab on its own and pursue multiple financing rounds in the future against a limited catalyst calendar over the next three years while we await lebrikizumab approval and launch. Based on the pending Dermavant IPO focused on a Phase III psoriasis biologic, we believe the category is still attractive to investors and strategics and we view this scenario as unlikely."
Recent DERM News
- Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference • GlobeNewswire Inc. • 09/09/2024 12:30:35 PM
- Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/04/2024 12:15:03 PM
- Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/13/2024 08:05:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:08:56 PM
- Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/12/2024 08:01:35 PM
- Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 • GlobeNewswire Inc. • 08/06/2024 08:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:18:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/23/2024 08:01:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:14:48 PM
- Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors • GlobeNewswire Inc. • 07/11/2024 08:05:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 08:45:38 PM
- Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase • GlobeNewswire Inc. • 05/15/2024 08:01:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:46:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:26 PM
- Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/13/2024 08:01:47 PM
- Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/07/2024 12:30:10 PM
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer • GlobeNewswire Inc. • 05/01/2024 08:01:30 PM
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 • GlobeNewswire Inc. • 04/25/2024 12:30:48 PM
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:27 PM
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea • GlobeNewswire Inc. • 03/18/2024 12:30:30 PM
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 12:30:01 PM
- Journey Medical Corporation to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/13/2024 12:30:14 PM
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:30:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:54:53 PM
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea • GlobeNewswire Inc. • 01/05/2024 01:30:12 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM